View in EDS

TNFα-inhibitors cycling with golimumab as second drug in inflammatory arthritis patients: Data from the multicenter GO-REAL registry.

Saved in:
Bibliographic Details
Title: TNFα-inhibitors cycling with golimumab as second drug in inflammatory arthritis patients: Data from the multicenter GO-REAL registry.
Authors: Isnardi, Carolina Ayelen1 (AUTHOR), Civit De Garignani, Emma Estela2 (AUTHOR), García Ciccarelli, Agustín2 (AUTHOR), Sanchez Alcover, Jimena2 (AUTHOR), Strusberg, Ingrid3 (AUTHOR), Baravalle, Marcos3 (AUTHOR), Castaños, Sol3 (AUTHOR), Morales, Liliana3 (AUTHOR), Palombo, Matias3 (AUTHOR), Albiero, Eduardo4 (AUTHOR), Gobbi, Carla4 (AUTHOR), Garcia Salinas, Rodrigo5 (AUTHOR), Magri, Sebastian5 (AUTHOR), Velozo, Edson6 (AUTHOR), Soriano, Enrique R.7 (AUTHOR), Vargas Caselles, Alfredo7 (AUTHOR), Palomino Romero, Luis Carlos7 (AUTHOR), Paira, Sergio8 (AUTHOR), Calvo, Romina8 (AUTHOR), Ortiz, Alberto8 (AUTHOR)
Source: Reumatología Clínica. Dec2024, Vol. 20 Issue 10, p539-546. 8p.
Subjects: RHEUMATOID arthritis, PSORIATIC arthritis, TUMOR necrosis factors, PATIENTS' attitudes, SPONDYLOARTHROPATHIES
Abstract (English): There are still controversies about the efficacy of cycling to a second tumor necrosis factor inhibitor (TNFi) in patients with inflammatory arthritis. The aim of this study was to evaluate survival, persistence and effectiveness of golimumab (GLM) in patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) with previous experience with other TNFi and to compare these results with TNFi naive patients. Observational cohort of consecutive patients with RA, PsA and axSpA who had started treatment with GLM according to medical indication. bDMARD naive and TNFi experienced patients were selected. A total of 147 (62.3%) bDMARD naive and 45 (19.1%) TNFi experienced patients were included. Patients were followed up for a total of 441.5 patients/year, 55 (28.6%) discontinued GLM, 42 (28.6%) and 13 (28.9%) in each group, respectively (p = 0.967). The majority (63.6%) suspended due to inefficacy, followed by lack of access (23.6%) and adverse events (9.1%). Median GLM survival was 74.0 months (95% CI 57.0, 91.0) and 71.0 months (95% CI 37.0, 105.0), in the bDMARD naive and TNFi experienced patients, respectively (p = 0.695). Drug persistence at 6, 12, 24 and 36 months was 92.8%, 88.1%, 76.1%, 65.4% and 93.1%, 77.4%, 74.2%, 68.5%, respectively. In the multivariable analysis, having public health insurance was associated with higher risk of drug discontinuation (HR 2.56, 95% CI 1.28–5.00, p = 0.008). TNFi experienced patients did not show significantly higher risk of GLM suspension (HR 1.35, 95% CI 0.70–2.57, p = 0.370). In this cohort, TNFi experienced patients had comparable survival and persistence of treatment with GLM. Having public health insurance was associated with lower drug retention rates. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Todavía existen controversias sobre la eficacia del cambio a un segundo inhibidor del factor de necrosis tumoral (iTNF) en pacientes con artritis inflamatoria. El objetivo de este estudio fue evaluar la supervivencia, la persistencia y la eficacia de golimumab (GLM) en pacientes con artritis reumatoidea (AR), espondiloartritis axial (EspAax) y artritis psoriásica (APs) con experiencia previa con otros iTNF y comparar estos resultados en pacientes sin tratamiento previo con iTNF. Cohorte observacional de pacientes consecutivos con AR, APs y EspAax que habían iniciado tratamiento con GLM según indicación médica. Se seleccionaron pacientes sin experiencia con DMARD biológicas y con experiencia en iTNF. Se incluyeron un total de 147 (62,3%) pacientes sin tratamiento previo con DMARDb y 45 (19,1%) pacientes con tratamiento previos con iTNF. Los pacientes fueron seguidos por un total de 441,5 pacientes/año, 55 (28,6%) descontinuaron GLM, 42 (28,6%) y 13 (28,9%) en cada grupo, respectivamente (p = 0,967). La mayoría (63,6%) suspendió por ineficacia, seguida de falta de acceso (23,6%) y eventos adversos (9,1%). La supervivencia de GLM mediana fue de 74,0 meses (IC 95%: 57,0, 91,0) y 71,0 meses (IC 95%: 37,0, 105,0), en los pacientes sin tratamiento previo con DMARDb y en los pacientes con experiencia con iTNF, respectivamente (p = 0,695). La persistencia del fármaco a los seis, 12, 24 y 36 meses fue del 92,8%, 88,1%, 76,1%, 65,4% y 93,1%, 77,4%, 74,2%, 68,5%, respectivamente. En el análisis multivariado, tener seguro de salud pública se asoció con mayor riesgo de discontinuación de GLM (HR 2,56, IC 95% 1,28-5,00, p = 0,008). Los pacientes con experiencia con iTNF no mostraron un riesgo significativamente mayor de suspensión de GLM (HR 1,35, IC 95%: 0,70-2,57, p = 0,370). En esta cohorte, los pacientes con experiencia previa con iTNF tuvieron una supervivencia y persistencia del tratamiento con GLM comparables. Tener cobertura de salud pública se asoció con tasas más bajas de retención de la droga. [ABSTRACT FROM AUTHOR]
Copyright of Reumatología Clínica is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 181115615
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: TNFα-inhibitors cycling with golimumab as second drug in inflammatory arthritis patients: Data from the multicenter GO-REAL registry.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Isnardi%2C+Carolina+Ayelen%22">Isnardi, Carolina Ayelen</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Civit+De+Garignani%2C+Emma+Estela%22">Civit De Garignani, Emma Estela</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22García+Ciccarelli%2C+Agustín%22">García Ciccarelli, Agustín</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sanchez+Alcover%2C+Jimena%22">Sanchez Alcover, Jimena</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Strusberg%2C+Ingrid%22">Strusberg, Ingrid</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Baravalle%2C+Marcos%22">Baravalle, Marcos</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Castaños%2C+Sol%22">Castaños, Sol</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Morales%2C+Liliana%22">Morales, Liliana</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Palombo%2C+Matias%22">Palombo, Matias</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Albiero%2C+Eduardo%22">Albiero, Eduardo</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gobbi%2C+Carla%22">Gobbi, Carla</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Garcia+Salinas%2C+Rodrigo%22">Garcia Salinas, Rodrigo</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Magri%2C+Sebastian%22">Magri, Sebastian</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Velozo%2C+Edson%22">Velozo, Edson</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Soriano%2C+Enrique+R%2E%22">Soriano, Enrique R.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vargas+Caselles%2C+Alfredo%22">Vargas Caselles, Alfredo</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Palomino+Romero%2C+Luis+Carlos%22">Palomino Romero, Luis Carlos</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Paira%2C+Sergio%22">Paira, Sergio</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Calvo%2C+Romina%22">Calvo, Romina</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ortiz%2C+Alberto%22">Ortiz, Alberto</searchLink><relatesTo>8</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Reumatología+Clínica%22">Reumatología Clínica</searchLink>. Dec2024, Vol. 20 Issue 10, p539-546. 8p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22RHEUMATOID+arthritis%22">RHEUMATOID arthritis</searchLink><br /><searchLink fieldCode="DE" term="%22PSORIATIC+arthritis%22">PSORIATIC arthritis</searchLink><br /><searchLink fieldCode="DE" term="%22TUMOR+necrosis+factors%22">TUMOR necrosis factors</searchLink><br /><searchLink fieldCode="DE" term="%22PATIENTS'+attitudes%22">PATIENTS' attitudes</searchLink><br /><searchLink fieldCode="DE" term="%22SPONDYLOARTHROPATHIES%22">SPONDYLOARTHROPATHIES</searchLink>
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: There are still controversies about the efficacy of cycling to a second tumor necrosis factor inhibitor (TNFi) in patients with inflammatory arthritis. The aim of this study was to evaluate survival, persistence and effectiveness of golimumab (GLM) in patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) with previous experience with other TNFi and to compare these results with TNFi naive patients. Observational cohort of consecutive patients with RA, PsA and axSpA who had started treatment with GLM according to medical indication. bDMARD naive and TNFi experienced patients were selected. A total of 147 (62.3%) bDMARD naive and 45 (19.1%) TNFi experienced patients were included. Patients were followed up for a total of 441.5 patients/year, 55 (28.6%) discontinued GLM, 42 (28.6%) and 13 (28.9%) in each group, respectively (p = 0.967). The majority (63.6%) suspended due to inefficacy, followed by lack of access (23.6%) and adverse events (9.1%). Median GLM survival was 74.0 months (95% CI 57.0, 91.0) and 71.0 months (95% CI 37.0, 105.0), in the bDMARD naive and TNFi experienced patients, respectively (p = 0.695). Drug persistence at 6, 12, 24 and 36 months was 92.8%, 88.1%, 76.1%, 65.4% and 93.1%, 77.4%, 74.2%, 68.5%, respectively. In the multivariable analysis, having public health insurance was associated with higher risk of drug discontinuation (HR 2.56, 95% CI 1.28–5.00, p = 0.008). TNFi experienced patients did not show significantly higher risk of GLM suspension (HR 1.35, 95% CI 0.70–2.57, p = 0.370). In this cohort, TNFi experienced patients had comparable survival and persistence of treatment with GLM. Having public health insurance was associated with lower drug retention rates. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: Todavía existen controversias sobre la eficacia del cambio a un segundo inhibidor del factor de necrosis tumoral (iTNF) en pacientes con artritis inflamatoria. El objetivo de este estudio fue evaluar la supervivencia, la persistencia y la eficacia de golimumab (GLM) en pacientes con artritis reumatoidea (AR), espondiloartritis axial (EspAax) y artritis psoriásica (APs) con experiencia previa con otros iTNF y comparar estos resultados en pacientes sin tratamiento previo con iTNF. Cohorte observacional de pacientes consecutivos con AR, APs y EspAax que habían iniciado tratamiento con GLM según indicación médica. Se seleccionaron pacientes sin experiencia con DMARD biológicas y con experiencia en iTNF. Se incluyeron un total de 147 (62,3%) pacientes sin tratamiento previo con DMARDb y 45 (19,1%) pacientes con tratamiento previos con iTNF. Los pacientes fueron seguidos por un total de 441,5 pacientes/año, 55 (28,6%) descontinuaron GLM, 42 (28,6%) y 13 (28,9%) en cada grupo, respectivamente (p = 0,967). La mayoría (63,6%) suspendió por ineficacia, seguida de falta de acceso (23,6%) y eventos adversos (9,1%). La supervivencia de GLM mediana fue de 74,0 meses (IC 95%: 57,0, 91,0) y 71,0 meses (IC 95%: 37,0, 105,0), en los pacientes sin tratamiento previo con DMARDb y en los pacientes con experiencia con iTNF, respectivamente (p = 0,695). La persistencia del fármaco a los seis, 12, 24 y 36 meses fue del 92,8%, 88,1%, 76,1%, 65,4% y 93,1%, 77,4%, 74,2%, 68,5%, respectivamente. En el análisis multivariado, tener seguro de salud pública se asoció con mayor riesgo de discontinuación de GLM (HR 2,56, IC 95% 1,28-5,00, p = 0,008). Los pacientes con experiencia con iTNF no mostraron un riesgo significativamente mayor de suspensión de GLM (HR 1,35, IC 95%: 0,70-2,57, p = 0,370). En esta cohorte, los pacientes con experiencia previa con iTNF tuvieron una supervivencia y persistencia del tratamiento con GLM comparables. Tener cobertura de salud pública se asoció con tasas más bajas de retención de la droga. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Reumatología Clínica is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=181115615
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.reuma.2024.09.007
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 539
    Subjects:
      – SubjectFull: RHEUMATOID arthritis
        Type: general
      – SubjectFull: PSORIATIC arthritis
        Type: general
      – SubjectFull: TUMOR necrosis factors
        Type: general
      – SubjectFull: PATIENTS' attitudes
        Type: general
      – SubjectFull: SPONDYLOARTHROPATHIES
        Type: general
    Titles:
      – TitleFull: TNFα-inhibitors cycling with golimumab as second drug in inflammatory arthritis patients: Data from the multicenter GO-REAL registry.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Isnardi, Carolina Ayelen
      – PersonEntity:
          Name:
            NameFull: Civit De Garignani, Emma Estela
      – PersonEntity:
          Name:
            NameFull: García Ciccarelli, Agustín
      – PersonEntity:
          Name:
            NameFull: Sanchez Alcover, Jimena
      – PersonEntity:
          Name:
            NameFull: Strusberg, Ingrid
      – PersonEntity:
          Name:
            NameFull: Baravalle, Marcos
      – PersonEntity:
          Name:
            NameFull: Castaños, Sol
      – PersonEntity:
          Name:
            NameFull: Morales, Liliana
      – PersonEntity:
          Name:
            NameFull: Palombo, Matias
      – PersonEntity:
          Name:
            NameFull: Albiero, Eduardo
      – PersonEntity:
          Name:
            NameFull: Gobbi, Carla
      – PersonEntity:
          Name:
            NameFull: Garcia Salinas, Rodrigo
      – PersonEntity:
          Name:
            NameFull: Magri, Sebastian
      – PersonEntity:
          Name:
            NameFull: Velozo, Edson
      – PersonEntity:
          Name:
            NameFull: Soriano, Enrique R.
      – PersonEntity:
          Name:
            NameFull: Vargas Caselles, Alfredo
      – PersonEntity:
          Name:
            NameFull: Palomino Romero, Luis Carlos
      – PersonEntity:
          Name:
            NameFull: Paira, Sergio
      – PersonEntity:
          Name:
            NameFull: Calvo, Romina
      – PersonEntity:
          Name:
            NameFull: Ortiz, Alberto
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: Dec2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 1699258X
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Reumatología Clínica
              Type: main
ResultId 1